drugset / Trial / NCT01950403

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

NCT01950403

RandomizedParallel-groupDouble-blindBasic science

Summary

This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer.

Timeline

Start
2013-09
Primary completion
2016-04-28
Completion
2018-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide 0.87 mg Oral

Indications